All News

syringe

Belimumab’s Sustained Impact in Lupus

d Mrinalini Dey, MD

In the wake of the EULAR 2023 guidelines on the management of SLE, it is perhaps pertinent that the EULAR 2024 congress features three abstracts from a large integrated analysis from five international Phase 3 belimumab trials in adults with active SLE (BLISS-76, BLISS-52, North East Asia, EMBRACE and BLISS-SC). Participants were randomised to belimumab (10 mg/kg/month intravenously or 200 mg/week subcutaneously) or placebo, plus standard therapy.

Read Article
#EULAR2024 OP0059 Propensity match scoring of 179 pts w #lupus nephritis in AURA & AURORA1 vs ALMS. Triple therapy (voclosporin + MMF2g/d + low dose GC) led to earlier, greater reduction in proteinuria, & improved safety profile vs dual (MMF3g/d or Cyclo + High dose GC) @RheumNow https://t.co/UdcuaRTtzC

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0017 If one target isn’t enough, why not two! Open label Phase I showed a double-pronged approach, compound BCMA-CD19 CAR Tcells (cCAR) improved clinical response, autoabs elimination & minimal infection in severe refractory #lupus nephritis @RheumNow #EULARBEST https://t.co/6MPHZKxKTB

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Can you ⬇️ #Glucocorticoids or #immunesuppressive in #SLE & change am’t of damage From Asia Pacific #lupus collab (Biologics not included) Compared 7.5 mg #prednisone or less Or DMARD 1/2 flared after LLDAS ⬇️dose didn’t prevent damage #EULAR2024 @eular_org @RheumNow https://t.co/QmjEz87Cvw

Links:

Janet Pope Janetbirdope ( View Tweet)

#EULAR2024 Cutaneous #lupus is variable & can be difficult to treat. Promising post-hoc data frm Phase 2 RCT showing Deucravacitinib (Tyk2-i) led to improvement & sustained CLASI-50 response in all subtypes (ACLE, SCLE, Chonic and Discoid) @RheumNow #EULARBEST https://t.co/ArAzdLYiYY

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0043 Data from UK BILAG-BR registry showed in n>100 patients w neuropsychiatric #lupus (NPSLE), over 2/3 improved with rituximab. NPSLE tended to occur with other #SLE features and with high level of organ damage @RheumNow https://t.co/q5olZgr6Pt

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0077 How can we improve Bcell killing and does deep depletion matter? Biomarkers from RCT showed Obinutuzumab led to profound circulatory depletion in #lupus nephritis & those w sustained depletion had better complete renal response than those who didn’t @RheumNow https://t.co/2KTZBR2njk

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Who needs intensive therapy in #lupus Intensive Rx in #SLE from 2 inception cohorts in Leeds Either #Cyclo or #biologics ⬆️ If low complement Within 2 yrs after #dx #SLEDAI >9 AntiRo+ OP0187 #EULAR2024 @RheumNow @eular_org https://t.co/oKhwMmHhSs

Links:

Janet Pope Janetbirdope ( View Tweet)
Conv3.jpg

EULAR 2024 - Day 1 Report

d Jack Cush, MD

Wednesday was Day One at EULAR 2024 in Vienna. While the day was a slow start, the poster halls and auditoriums quickly filled with thousands of rheumatologists, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.

Read Article
Telemedicine

AI meets Rheumatology: ChatGPT and patient response optimization

d Bella Mehta, MBBS, MS

Large language models, such as ChatGPT, are advanced systems trained on vast amounts of text data, far exceeding what a human can read in a lifetime, to understand and generate human-like language. With these tools at our disposal, they are inevitably making their way into healthcare. One notable example is response optimization for SLE patients, as highlighted in abstract #0989.

Read Article
3 facts in #lupus to make you think 🤔 💧biomarkers in #SLE blood & #urine May predict #activity OP0255 #Membranous #nephritis is serious in SLE @ZahiTouma POS0732 #prednisone dose irrelevant for #damage if in LLDAS -no diff between 7.5mg vs 5mg OP0124 #EULAR2024 @RheumNow

Janet Pope Janetbirdope ( View Tweet)

#Hope for patients with #active #SLE The next hurdle is getting through ▶️Phase3 #RCTs And ▶️Obtaining drug reimbursement so patients can get access to effective #lupus #Rx #EULAR2024 @RheumNow @eular_org https://t.co/sGzQXO4A2r

Links:

Janet Pope Janetbirdope ( View Tweet)

#EULAR204 Encouraging Timeline for future potential treatments for #SLE #Lupus @LUPUSUK @LupusMadrid @Lupus_Chat @LupusEurope https://t.co/SLKc0XCtFq

Links:

Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
OP0048 Impressive CLASI (lupus skin index score) with #deucravacitinib - data presented by Dr C Arriens #EULAR24 @RheumNow #WiR https://t.co/EuQdwuolN6

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Novel B cell depleters! Bispecific T cell engagers (BiTEs) being studied for #SLE & #RA as a way to get CAR-T cell like responses but more accessible w/less risk for CK release syndrome. #EULAR24 T cell-engaging therapies — BiTEs and beyond | Nature Reviews Clinical Oncology

TheDaoIndex KDAO2011 ( View Tweet)

#EULAR2024 Please find my article on a preview of interesting abstract to look out for for #lupus #SLE therapies at this year’s congress @RheumNow https://t.co/TEtrDWq3BF https://t.co/1zIIxsaeL2

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 Please find my article on a preview of interesting abstract to look out for for #lupus #SLE therapies at this year’s congress @RheumNow https://t.co/TEtrDWq3BF https://t.co/1zIIxsaeL2

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Genetic Risk scoring can predict adverse outcomes in #SLE #EULAR2024 @RheumNow https://t.co/g9kGdRkCOh

Links:

Bella Mehta bella_mehta ( View Tweet)
Systematic Review of #SLE pregnancies in Latin America – 44articles, 4K patients, Hispanic/ Latino with increased preeclampsia when they have LN #EULAR2024 Abst#0986 @RheumNow

Bella Mehta bella_mehta ( View Tweet)

Digital technologies and health in #SLE can be integrated at several stages, but still a needs a bridge between #AI and #humanintellegence #EULAR2024 @Lupusreference @RheumNow https://t.co/1aN8QPgVWn

Links:

Bella Mehta bella_mehta ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×